Ovarian Endometrioid Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Ovarian Endometrioid Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer [Phase 1]
Phase 1 clinical trial assessing different dosing amounts of the drug combination M1774 and ZEN-3694 for recurrent ovarian and endometrial c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating Bevacizumab in combination with Anetumab Ravtansine or Paclitaxel for refractory ovarian, fallopian tube, …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with bevacizumab, with or without the anti-CD40 agonist CDX-1140, for recur…
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer [Phase 2]
This is a Phase 2 clinical trial evaluating tazemetostat for recurrent ovarian or endometrial cancers; the study is currently not recruiting…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of ruxolitinib phosphate in combination with paclitaxel and carboplatin for S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-09-20Clinical Trial Update: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) [Phase 2]
Phase 2 Imperial College London study evaluating dual mTORC1/2 inhibition in advanced or recurrent epithelial ovarian, fallopian tube, or pr…
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab, bevacizumab, and cyclophosphamide in recurrent ovarian, fallopian tube, or primary peritone…
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of everolimus and letrozole in patients with recurrent hormone receptor-positive ovarian…
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating elesclomol sodium with paclitaxel in patients with recurrent or persistent ovarian epithelial cancer, fallopian tub…
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer [NA]
A terminated clinical trial evaluated a triple antiemetic regimen (granisetron, aprepitant, and dexamethasone) to prevent chemotherapy-induc…
-
CLINICAL_TRIALS trial_result · 2014-07-17Clinical Trial Update: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial update for A6 in treating persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary perito…